-
TearLab's Co-Promotion With PRN A Positive, But Rodman & Renshaw Isn't Raising Its Estimates
Friday, October 14, 2016 - 3:57pm | 336TearLab Corp (NASDAQ: TEAR) announced on Thursday that it had inked a co-promotion agreement with Physician Recommended Nutriceuticals (PRN), a privately-held eye health company. Under the arrangement, the firms will join efforts to promote PRN’s omega-three formulations, including Dry Eye...
-
Resolute Energy Initiated At Buy Given 'Impressive' Permian Basin Potential
Wednesday, October 5, 2016 - 9:36am | 274Rodman & Renshaw analyst Noel Parks initiated coverage on Resolute Energy Corp (NYSE: REN) with a Buy rating and $32 price target. The bullish rating is based on a risked Net Asset Value (NAV) and optimism regarding Permian Basin wells, specifically in the Delaware Basin, said Parks....
-
Rodman & Renshaw Prescribe A $6 Price Target For Cancer Genetics
Monday, September 26, 2016 - 9:10am | 302Cancer Genetics Inc (NASDAQ: CGIX) represents “a highly differentiated investment opportunity, given its broad pipeline of tests…and with its ability to generate high-margin revenue from partnerships with biopharmaceutical firms that are seeking to develop theranostic solutions for...
-
Sum-Of-The-Parts Valuation Leads Rodman & Renshaw To Initiate Oasmia Pharmaceuticals At Buy With A $6 Target
Monday, September 12, 2016 - 2:26pm | 314Oasmia Pharmaceutical AB - American Depositary Shares (NASDAQ: OASM) enjoyed a healthy spike higher on volume Monday, perhaps due in part to an initiation of coverage from analysts at Rodman & Renshaw. Analyst Raghuram Selvaraju initiated Oasmia with a Buy rating and a $6 price target. With...
-
Rodman & Renshaw Sees 52% Upside In Hecla Mining
Tuesday, September 6, 2016 - 11:22am | 366Rodman & Renshaw’s Heiko F. Ihle believes Hecla Mining Company (NYSE: HL)'s long-term focus, along with its portfolio of “long-lived” assets, would offer investors good exposure to any future upside in silver and gold prices. Ihle initiated coverage of the company with a Buy...
-
Ring Energy's Business Model Well-Suited For This Oil Price Environment, Says Rodman & Renshaw
Monday, August 29, 2016 - 10:03am | 390Rodman & Renshaw picked up Ring Energy Inc (NYSE: REI) in the energy exploration and production sector and initiated the company with a Buy rating on multiple catalysts. Analyst Noel Parks attached a price target of $15 based on risked net asset valuation of reserves. Best Suited In a tough oil...
-
HTG Molecular's Profiling System 'Requires Less But Delivers More'
Monday, August 22, 2016 - 10:18am | 356Rodman & Renshaw initiated coverage on HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares with a Buy rating. The brokerage has a price objective of $5 on the company's stock, citing that the molecular profiling system required less sample material to deliver more. Analysts Raghuram Selvaraju...
-
5 Stocks Under $5 Making Headlines
Wednesday, August 3, 2016 - 10:23am | 799Penny stocks typically don’t cost a penny anymore. Companies trading as high as $5 per share are now considered “penny stocks,” and for good reason. These stocks lack the stability and performance reliability of those with a bigger market cap. With that said, buying a fiver doesn...
-
Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares
Thursday, July 21, 2016 - 12:05pm | 211Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain. Related Link:...
-
Rodman & Renshaw Initiates Orion Energy At Buy, Attaches $2.50 Target
Monday, July 18, 2016 - 4:04pm | 557Rodman & Renshaw has started coverage of Orion Energy Systems, Inc. (NASDAQ: OESX) with a Buy rating and price target of $2.50, which implies an upside of 108 percent over Friday's close. Recent Performance Orion Energy makes energy efficient lighting systems, with a primary focus of expanding...
-
Why This Analyst Sees TearLab Shares Tripling
Tuesday, July 12, 2016 - 11:22am | 327Rodman & Renshaw’s Raghuram Selvaraju mentioned that TearLab Corp (NASDAQ: TEAR)'s Osmolarity System for the diagnosis of dry eye disease (DED) is “the first and only objective DED diagnostic test in the U.S. that has FDA clearance and CLIA waiver.” Selvaraju initiated...
-
Valeant Crossed $20 Today; Rodman & Renshaw Sees Shares Getting To $90
Wednesday, July 6, 2016 - 2:00pm | 278It’s not often that a Wall Street analyst will set a price target for a big-name stock that represents nearly 300 percent upside. But in a new research note, Rodman & Renshaw’s Raghuram Selvaraju did just that when he set a $90 price target for Valeant Pharmaceuticals Intl Inc (...
-
Rodman & Renshaw Sees 160% Upside For NeuroMetrix
Tuesday, June 28, 2016 - 12:04pm | 359Rodman & Renshaw started coverage of Neurometrix Inc (NASDAQ: NURO) with a Buy rating and a target price of $4.50, implying an upside of 160 percent. NeuroMetrix is medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and...
-
Further Growth Projected At LabStyle Innovations
Monday, May 23, 2016 - 2:24pm | 275Rodman & Renshaw maintains its Buy rating and $12 price target on LabStyle Innovations Corp (NASDAQ: DRIO) after the company's better-than-expected first-quarter results. LabStyle Innovations reported lower-than-projected net loss of $0.33 per share versus the brokerage's estimate of $0.38 per...
-
Here's Why Presbia Is Worth $14/Share, Despite Plummeting Monday
Monday, May 23, 2016 - 12:21pm | 251Rodman & Renshaw maintains a Buy rating on Presbia PLC (NASDAQ: LENS) after an interim data from the company showed that its corneal inlay product, the Flexivue Microlens, can achieve "significant improvement in uncorrected near vision acuity without loss of distance vision performance." "An...